Avistone is an oncology company focused on developing innovative therapies for patients with significant unmet medical needs globally.  Avistone has an extensive pipeline of targeted therapies including two clinical-stage drug candidates and several ongoing programs in the pre-clinical development stage.  The Company’s lead asset is PLB1001, a small-molecule inhibitor that targets MET tyrosine kinase activity, including aberrant activity observed with METexon14 skipping (genetic) alterations in NSCLC tumors and in other solid tumors.  The company's second clinical asset is PLB1004, a potent inhibitor of EGFR tyrosine kinases (TKI), including aberrant activity observed with EGFR exon20 insertion (genetic) mutations in NSCLC tumors.  

Avistone Biotechnology Co., Inc

Euro

DNSSEC

Pound Sterling

Japanese Yen

Xinnet DNS

Hepeng Shi

Chairman, CEO, and founder

Beijing Companies With More Than 10 Employees

Biotechnology Companies With More Than 100 Employees

Asia Companies With More Than 10 Employees (Top 10K)

Asia-Pacific (APAC) Biotechnology Companies with Early Stage Venture Funding

Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.

IDG Capital

SDIC Fund Management

Series B - Avistone Pharmaceuticals

Vivo Capital

Series A - Avistone Pharmaceuticals

Beijing

China

Asia

Avistone Pharmaceuticals

C-Met inhibitor ANS-014004 overcomes clinical MET mutation with antitumor activity

A small-molecule selective MET inhibitor used to treat non-small cell lung cancer (NSCLC) and glioma by inhibiting the activation of the MET pathway.

A small-molecule inhibitor for epidermal growth factor receptor (EGFR) used to treat late-stage non-small cell lung cancer caused by EGFR mutation.

A research program focused on developing compounds that address resistance in type Ib c-Met inhibitors and common Met gene abnormalities, including exon 14 skipping mutations and gene amplification.

Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.

Incyte

Syndax is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment.

Syndax

Leap Therapeutics is a biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer treatment.

Leap Therapeutics

Eidos Therapeutics is a biopharmaceutical company dedicated to developing novel therapies for rare and life-threatening diseases.

Eidos Therapeutics

Oncora Medical is a healthcare technology company that provides precision medicine solutions for cancer care.

Oncora Medical

Avistone is a biotechnology company that develops innovative drugs. The company's core team consists of experienced professionals with expertise in early drug development, clinical study, industrial production, and commercial development.

Avistone

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	May 3, 2024 1:33 PM	8c993918
public peers	general	May 3, 2024 1:33 PM	50eec722
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 3, 2024 1:33 PM	78f21395
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:09 AM	13e422a2
crunchbase profile	general	Nov 25, 2024 9:49 AM	77b7cb88
li profile	general	May 3, 2024 1:33 PM	6aea0657
translate crunchbase fundingrounds	general	Nov 25, 2024 2:05 PM	9e2a58e3
peers	general
news basic	general	May 3, 2024 1:33 PM	10031d7a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AVISTONEBIO

Avistone